TORONTO, ONTARIO--(Marketwire - Oct. 1, 2012) - Dr. Anatoly Langer, the Chairman of CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), announced that MD Primer Inc. ("MDP", which is under Dr. Langer's control and direction) has acquired 6,000,000 common shares of CardioComm Solutions through the exercise of 6,000,000 common share purchase warrants at a price of $0.10 per share. The shares acquired represent approximately 6.1% of the issued and outstanding common shares of CardioComm Solutions.
Dr. Langer, personally and through holding companies including MDP, owns or has control and direction over an aggregate of 57,530,581 common shares of CardioComm Solutions, representing approximately 58.45% of CardioComm Solutions' issued and outstanding common shares. To review the report associated with this news release, please go to CardioComm Solutions' profile on SEDAR at www.sedar.com or contact the Company at 1.800.725.6585, ext. 264.
Dr. Langer also announced that it was his intention to cause MDP to sell 1,500,000 common shares of CardioComm Solutions to Etienne Grima, CardioComm Solutions' CEO, at a price of $0.10 per common share. This proposed sale is contemplated in the Form 45-102F1 filed by Dr. Langer today on SEDAR. Before becoming the Company's full-time CEO, Mr. Grima served as MDP's full time Chief Operating Officer. The purpose of the proposed sale of the shares by MDP to Mr. Grima at a discount to the current trading price of the shares is to provide Mr. Grima with additional compensation for his past services to MDP.
"Mr. Grima has tremendous experience and energy and will now be able to focus his talent as the full time CEO of the CardioComm Solutions. As a shareholder of the Company, I am very happy with this development and energized by our future opportunities in developing the HeartCheck™ brand under Mr. Grima's leadership," stated Dr. Langer.
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of MD Primer and certain of the plans and objectives of MD Primer with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Dr. Langer has previously purchased shares from CardioComm Solutions for investment purposes, and in the future may further purchase, hold, vote, trade, dispose or otherwise deal in the common shares of CardioComm Solutions in such manner as he deems advisable to benefit from changes in market prices of such common shares, changes in the operations of CardioComm Solutions, its business strategy or prospects, or from a sale or merger of CardioComm Solutions.
Dr. Anatoly Langer
To review the report associated with this news release, please go to CardioComm's profile on SEDAR at www.sedar.com or contact CardioComm at 1.800.725.6585, ext. 264.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.